Loading organizations...
§ Private Profile · La Jolla, CA, USA
Viridos is a technology company.
Viridos is a biotechnology company that develops genomic-driven solutions to global energy and environmental challenges. It specifically harnesses the power of photosynthesis to create low-carbon intensity biofuels. By engineering microalgae, the company provides sustainable alternatives to traditional energy sources, addressing the urgent need for climate change mitigation through biological systems.
The company originated as Synthetic Genomics Inc., co-founded in 2005 by genomics pioneer J. Craig Venter and Nobel Laureate Hamilton O. Smith. Their foundational insight centered on applying advanced synthetic biology principles to develop novel energy solutions. Venter’s extensive background in genomics provided the scientific bedrock for the company’s innovative approach to biological engineering.
Viridos' products serve various industries and sectors seeking to decarbonize their operations and adopt cleaner energy. The company's long-term vision focuses on creating transformative, eco-friendly solutions. It aims to significantly contribute to global sustainability by leveraging biological systems to mitigate climate change and provide a path towards a more environmentally responsible future.
Viridos has raised $25.0M across 1 funding round.
Viridos has raised $25.0M in total across 1 funding round.
Viridos has raised $25.0M in total across 1 funding round.
Viridos's investors include Breakthrough Energy Ventures, Gaetan Bonhomme, Chevron Technology Ventures, Mike Leskinen.
Viridos has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2023 | $25M Series A | Breakthrough Energy Ventures, Gaetan Bonhomme | Chevron Technology Ventures, Mike Leskinen | Announced |
Viridos is a biotechnology company specializing in synthetic biology to engineer microalgae for producing low-carbon intensity biofuels, targeting heavy transportation sectors like aviation, trucking, and maritime shipping.[1][2][3] Formerly Synthetic Genomics Inc. (SGI), it harnesses photosynthesis in microalgae to create sustainable alternatives to fossil fuels, addressing global energy and climate challenges through scalable bio-production platforms.[1][2][5] The company serves industries seeking decarbonization solutions, solving the problem of high-carbon fuels by achieving up to seven times higher oil productivity from engineered algae strains.[1][6]
With 116 employees based in La Jolla, California, Viridos demonstrates growth momentum through recent funding, including a $25 million raise in 2023 for algae biofuel advancement, and an active patent portfolio of 149 filings in molecular biology, biotechnology, and genetics.[2][3][4][6]
Viridos traces its roots to 2005, when Synthetic Genomics Inc. (SGI) was founded in La Jolla, California, as a pioneer in synthetic biology and genomics.[1][2][3] In September 2021, SGI rebranded to Viridos to emphasize its focus on "green gold"—algae-derived biofuels—building on early innovations like the BioXP 3200 automated DNA synthesis system launched in 2015.[1][3]
The idea emerged from applying software engineering, genetic engineering, and bioprocessing to redesign biological systems for sustainability, initially targeting biofuels, agriculture, and medicine.[1] Pivotal early traction came from high-profile partnerships, such as with ExxonMobil for biodiesel, Monsanto for crop microbiomes, and United Therapeutics for organ transplantation, validating its tech across research, bioproduction, and applied products.[1] Key founders and leaders, though not individually named in records, leveraged expertise in algal genetics to shift from broad genomics to climate-focused biofuels.[2][3]
Viridos stands out in synthetic biology through:
Viridos rides the sustainable aviation fuel (SAF) and renewable energy wave, capitalizing on global demand for low-carbon alternatives amid aviation's push for net-zero emissions—exemplified by partnerships like Neste-FedEx and market projections for algae biofuels.[2][4][6] Timing aligns with 2025 advances in gene editing and bio-manufacturing, fueling a synthetic biology market projected to reach $84.7 billion by 2035, where algae's high yield per acre outpaces crops.[4]
Market forces like clean energy mandates, high oil prices, and biorefinery expansions (e.g., Calumet's SAF capacity surge) favor Viridos, positioning it to influence the bioeconomy by enabling scalable, drop-in fuels for trucking and maritime sectors.[2][5][6] As a privately held innovator, it shapes ecosystem standards through genomic tools and IP, bridging research to industrial deployment.[1][3]
Viridos is poised to scale commercial biofuel production, leveraging 2025 patent wins in genome editing and algae productivity amid booming SAF demand.[4][6] Trends like AI-driven bioprocessing, policy incentives for renewables, and algae's edge in land efficiency will accelerate its path to market leadership, potentially through new facilities or expanded partnerships.[2][4]
Its influence may evolve from R&D pioneer to bioenergy supplier, driving the shift to a sustainable bioeconomy—echoing its origin as a genomics trailblazer now fueling climate solutions.[1][3]